Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation (Nasdaq: LFVN) is a Delaware-incorporated health and wellness company that focuses on nutrigenomics and cellular activation, and its SEC filings provide detailed insight into its operations, governance, and financial performance. As a public company, LifeVantage files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements on Schedule 14A, among other documents.
Through these filings, investors can review information about LifeVantage’s activator-based product portfolio, which includes the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, P84, AXIO nootropic energy drink mixes, activation-supporting nutrients, the TrueScience skin and hair care line, and Petandim. The filings also describe the company’s direct selling model, under which independent Consultants sell products to Customers and share the business opportunity with entrepreneurs.
Current reports on Form 8-K document material events such as financial results announcements, executive officer changes, and other significant corporate developments. Definitive proxy statements (DEF 14A) provide detail on board composition, executive compensation, equity incentive plans like the 2017 Long-Term Incentive Plan, and matters submitted to stockholder votes, including director elections, say-on-pay proposals, and auditor ratification. Voting results for these proposals are also reported in 8-K filings.
On this page, LifeVantage filings are updated as they are made available through the EDGAR system. AI-powered tools summarize key sections of lengthy documents, helping readers understand topics such as revenue trends, non-GAAP measures like adjusted EBITDA and adjusted earnings per share, stock-based compensation plans, and governance structures without reading every line. Users can also review disclosures related to dividends, share repurchases, and risk factors referenced in the company’s periodic reports.
For those researching LFVN, this filings archive offers a structured view of LifeVantage’s regulatory history, financial reporting, and corporate decision-making, with AI-generated highlights to make complex filings more accessible.
Steven R. Fife, President and CEO and director of Lifevantage Corp (LFVN), reported insider transactions on 08/31/2025. Two tranches of previously granted performance restricted stock units converted into common stock: 90,718 shares (granted 08/24/2023) and 108,960 shares (granted 08/26/2024). Those PRSUs convert one-for-one into common shares and were reported as acquired at $0 under Rule 16 reporting codes. Separately, 98,177 shares were disposed of at a reported price of $13.10, leaving the reporting person with 761,001 and 859,178 total shares following the respective transactions as shown on the form.
Lifevantage Corp (LFVN) reporting person Alissa Neufeld recorded equity activity consisting of performance restricted stock units (PRSUs) and a disposition of common stock. The filing shows PRSUs granted in 2023 and 2024 that convert one-for-one into common stock, two grant-related transactions adding 14,498 and 18,886 shares (Transaction Code M) at $0 per share, and a sale (Transaction Code F) of 15,729 shares at $13.10 per share. After these transactions the reporting person beneficially owned 118,260 common shares.
The derivative section shows the PRSUs underlying 14,498 and 18,886 units, with post-transaction derivative beneficial ownership reported as 4,832 and 9,443 respectively. The filing states the PRSUs vest upon meeting pre-established time-based and financial performance criteria and convert into common stock on a one-for-one basis.
Julie Boyster, identified as an Officer (Chief Marketing Officer), reported Section 16 transactions in Lifevantage Corp (LFVN) on 08/31/2025. Two grants of Performance Restricted Stock Units (PRSUs) converted or vested resulting in acquisitions: 18,934 shares (from a PRSU grant on 08/24/2023) and 27,966 shares (from a PRSU grant on 08/26/2024). The filing states PRSUs convert into common stock on a one-for-one basis. The holder also reported a disposition of 23,293 shares at a price of $13.10 each. Following the reported transactions, the form shows the reporting person beneficially owned 151,923 shares directly. The form is signed by a power of attorney on behalf of Julie Boyster.
Alissa Neufeld, General Counsel of Lifevantage Corp (LFVN), received equity awards on 08/26/2025. The Form 4 shows an award of 9,036 stock units and 13,554 Performance Restricted Stock Units (PRSUs). After the grant, Ms. Neufeld beneficially owns 100,605 shares of common stock and 13,554 PRSU equivalents. The stock units vest with 5/12 of the award on September 10, 2026 and the remainder in equal installments on the tenth day of the third month of each of seven subsequent calendar quarters. The PRSUs vest only if performance targets are met (target payout shown); upon maximum performance the award may pay up to 200% of target, with vested portions scheduled 34% on Sept 10, 2026, 33% on Sept 10, 2027, and 33% on Sept 10, 2028.
Lifevantage Corp (LFVN) reported a Form 4 showing equity awards to Julie Boyster, the company's Chief Marketing Officer. The filing discloses a non‑derivative grant of 13,102 common stock units on 08/26/2025, increasing her directly held common shares to 128,316. The filing also shows 19,654 Performance Restricted Stock Units (PRSUs) granted the same date, representing rights to receive that many shares if performance targets are met; the PRSUs count as 19,654 underlying shares for beneficial ownership. The stock units vest over time subject to continued service: 5/12 of the stock unit award vests on September 10, 2026, with the remainder in equal installments across seven calendar quarters thereafter. The PRSUs vest only to the extent financial performance criteria are achieved and, if earned, vest in three tranches on September 10, 2026, 2027 and 2028 (34%, 33%, 33%). The Form 4 was signed by a power of attorney on 08/28/2025.
Lifevantage Corp (LFVN) reporting person Steven R. Fife, President and CEO and a director, received non‑derivative and derivative equity awards on 08/26/2025. He was granted 48,193 stock units that represent rights to receive common stock and will hold 659,500 shares beneficially following the grant. He also received 72,289 Performance Restricted Stock Units (PRSUs) at target, with each PRSU representing one share at $0 exercise price; PRSU vesting is contingent on performance and continued service.
The stock units vest partly on September 10, 2026 and then in installments across seven quarters; PRSU vesting, if earned, vests 34% on September 10, 2026, 33% on September 10, 2027 and 33% on September 10, 2028. The Form 4 was signed by a power of attorney on 08/28/2025.
Lifevantage Corp (LFVN) reporting person Kristen Cunningham, Chief Sales Officer, received equity awards on 08/26/2025. The filing shows a grant of 12,349 stock units (each convertible to one share) and 18,524 performance restricted stock units (PRSUs) representing target-level awards. Following the transactions, Cunningham beneficially owns 116,351 shares and 18,524 PRSU-equivalent shares reported as direct ownership. The stock units vest over time subject to continued service, and the PRSUs vest only if specified performance criteria are met, with potential payout up to 200% of target.
Lifevantage Corp (LFVN) Chief Financial Officer Carl Aure received equity awards on 08/26/2025. The Form 4 reports an award of 10,241 stock units that represent rights to receive common shares and 15,361 Performance Restricted Stock Units (PRSUs) that are earned based on specified financial performance criteria. After the reported transactions, the filing shows 143,544 shares beneficially owned and 15,361 derivative shares from PRSUs. The stock units vest over time with a schedule beginning September 10, 2026, and the PRSUs vest contingent on performance and continued service with vesting dates in 2026–2028. The form was signed by power of attorney on 08/28/2025.